Drug Design Development and Therapy · 2016 · 34 citations · 28 references
ENT was mainly metabolized through the "parent→M2→M1" pathway based on in vitro and in vivo elimination behavior. The observed in vitro deuterium isotope effect translated into increased exposure of the deuterated analog in rats. Once the carbon-hydrogen was replaced with carbon-deuterium (C-D) bonds, the major metabolic pathway was retarded because of the relatively stable C-D bonds. The systemic exposure to d3-ENT can increase in humans, so the dose requirements can be reduced appropriately.
28
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.5K citations · Full text
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science · 2009 · 2.3K citations · Full text
Heavy drugs draw heavy interest from pharma backers
Alla Katsnelson · Nature Medicine · 2013 · 220 citations · Full text